Jerini Submits Icatibant NDA; Asks FDA For Priority Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Priority review would give the company’s hereditary angioedema treatment a user fee date in late April/early May 2008, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
FDA “Approvable” For Lev’s Cinryze Opens Window For Jerini To Reach Market First
Lev now targets mid-2008 for FDA approval for the C1 inhibitor for hereditary angiodema.
FDA “Approvable” For Lev’s Cinryze Opens Window For Jerini To Reach Market First
Lev now targets mid-2008 for FDA approval for the C1 inhibitor for hereditary angiodema.
Jerini’s Firazyr For HAE Gets Advisory Committee Review Feb. 20
FDA’s Pulmonary-Allergy Drugs Advisory Committee is slated to review icatibant for hereditary angioedema.